Functional genomics and cancer drug target discovery

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 3, 2010, Pages 284-293

  Moody, S E ^a,b,c   Boehm, J S ^c   Barbie, D A ^a,c,d   Hahn, W C ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Cancer; Functional genomics; Molecular target; Oncogene; Synthetic lethality; Tumor suppressor

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; GEFITINIB; MICRORNA; OLAPARIB; PACLITAXEL; RAPAMYCIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

CANCER INHIBITION; CANCER RESEARCH; DNA MICROARRAY; DRUG TARGETING; FUNCTIONAL GENOMICS; GENE LIBRARY; GENE REPRESSION; GENETIC SCREENING; HUMAN; LETHALITY; NEOPLASM; NONHUMAN; ONCOGENE; OPEN READING FRAME; PHENOTYPE; REVIEW; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMOSOME MAPPING; DRUG DISCOVERY; GENOME; GENOMICS; HUMANS; MUTATION; NEOPLASMS; NERVOUS SYSTEM NEOPLASMS; ONCOGENES;

EID: 77953205629     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. TCGA: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 455(7216):1061-1068.
2. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L et al: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 456(7218): 66-72.
3. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 361(11):1058-1066.
4. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S et al: Patterns of somatic mutation in human cancer genomes. Nature (2007) 446(7132):153-158.
5. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, Lin ML, Beare D, Lau KW, Greenman C, Varela I et al: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2010) 463(7278):184-190.
6. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT et al: The landscape of somatic copy-number alteration across human cancers. Nature (2010) 463(7283): 899-905.
7. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise I, Dupuy AJ, Collier LS et al: A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science (2009) 323(5922):1747-1750.
8. Ellis J, Bernstein A: Gene targeting with retroviral vectors: Recombination by gene conversion into regions of nonhomology. Mol Cell Biol (1989) 9(4):1621-1627.
9. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14-3-3- is required to prevent mitotic catastrophe after DNA damage. Nature (1999) 401(6753):616-620.
10. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R et al: A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 428(6981):431-437.
11. Paddison PJ, Silva JM, Conklin DS, Schlabach M, Li M, Aruleba S, Balija V, O'Shaughnessy A, Gnoj L, Scobie K, Chang K et al: A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 428(6981):427-431.
12. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, Lam LT, Dave S, Yang L, Powell J, Staudt LM: A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 441(7089):106-110.
13. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, Carpenter AE et al: A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 124(6): 1283-1298.
14. Zamore PD, Tuschl T, Sharp PA, Bartel DP: RNAi: Doublestranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell (2000) 101(1): 25-33.
15. Bernstein E, Caudy AA, Hammond SM, Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 409(6818):363-366.
16. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ: Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 305(5689):1437-1441.
17. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T: Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell (2002) 110(5):563-574.
18. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA et al: The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 10(2):202-210.
19. Nakano H, Miyazawa T, Kinoshita K, Yamada Y, Yoshida T: Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer (2009): doi:10.1002/ijc.25143.
20. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E et al: A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell (2006) 124(6):1169-1181.
21. Jacobs BL, Langland JO: When two strands are better than one: The mediators and modulators of the cellular responses to double-stranded RNA. Virology (1996) 219(2):339-349.
22. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494-498.
23. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA (2001) 98(17):9742-9747.
24. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 65(19):8984-8992.
25. Amarzguioui M, Rossi JJ, Kim D: Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett (2005) 579(26):5974-5981.
26. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 296(5567):550-553.
27. Lamesch P, Li N, Milstein S, Fan C, Hao T, Szabo G, Hu Z, Venkatesan K, Bethel G, Martin P, Rogers J et al: hORFeome v3.1: A resource of human open reading frames representing over 10,000 human genes. Genomics (2007) 89(3):307-315.
28. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B et al: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA (2002) 99(26):16899-16903.
29. Rolfs A, Hu Y, Ebert L, Hoffmann D, Zuo D, Ramachandran N, Raphael J, Kelley F, McCarron S, Jepson DA, Shen B et al: A biomedically enriched collection of 7000 human ORF clones. PLoS ONE (2008) 3(1):e1528.
30. Temple G, Lamesch P, Milstein S, Hill DE, Wagner L, Moore T, Vidal M: From genome to proteome: Developing expression clone resources for the human genome. Hum Mol Genet (2006) 15(Spec No 1):R31-43.
31. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K et al: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet (2004) 36(1):40-45.
32. The Orfeome Collaboration: (2005). www.orfeomecollaboration. org
33. Castle JC, Zhang C, Shah JK, Kulkarni AV, Kalsotra A, Cooper TA, Johnson JM: Expression of 24,426 human alternative splicing events and predicted cis regulation in 48 tissues and cell lines. Nat Genet (2008) 40(12):1416-1425.
34. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB: Alternative isoform regulation in human tissue transcriptomes. Nature (2008) 456(7221):470-476.
35. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ: Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet (2008) 40(12):1413-1415.
36. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H et al: Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 129(6): 1065-1079.
37. Melnick JS, Janes J, Kim S, Chang JY, Sipes DG, Gunderson D, Jarnes L, Matzen JT, Garcia ME, Hood TL, Beigi R et al: An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA (2006) 103(9): 3153-3158.
38. Ziauddin J, Sabatini DM: Microarrays of cells expressing defined cDNAs. Nature (2001) 411(6833):107-110.
39. Bailey SN, Ali SM, Carpenter AE, Higgins CO, Sabatini DM: Microarrays of lentiviruses for gene function screens in immortalized and primary cells. Nat Methods (2006) 3(2): 117-122.
40. Brummelkamp TR, Fabius AW, Mullenders J, Madiredjo M, Velds A, Kerkhoven RM, Bernards R, Beijersbergen RL: An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2(4): 202-206.
41. Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR, Elledge SJ, Hannon GJ, Chang K: Profiling essential genes in human mammary cells by multiplex RNAi screening. Science (2008) 319(5863):617-620.
42. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X, Hinkle G, Boehm JS, Beroukhim R, Weir BA, Mermel C et al: Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA (2008) 105(51):20380-20385.
43. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, Westbrook TF et al: Cancer proliferation gene discovery through functional genomics. Science (2008) 319(5863):620-624.
44. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, Xuan Z, Zuber J, Wigler M, Hicks J, McCombie RW et al: Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 16(4):324-335.
45. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR et al: An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 135(5):852-864.
46. Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT: In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat Genet (2009) 41(10):1133-1137.
47. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG et al: CDK8 is a colorectal cancer oncogene that regulates -catenin activity. Nature (2008) 455(7212):547-551.
48. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR: An elaborate pathway required for Ras-mediated epigenetic silencing. Nature (2007) 449(7165):1073-1077.
49. Neumann B, Walter T, Heriche JK, Bulkescher J, Erfle H, Conrad C, Rogers P, Poser I, Held M, Liebel U, Cetin C et al: Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. Nature (2010) 464(7289):721-727.
50. Neumann B, Held M, Liebel U, Erfle H, Rogers P, Pepperkok R, Ellenberg J: High-throughput RNAi screening by time-lapse imaging of live human cells. Nat Methods (2006) 3(5):385-390.
51. Antczak C, Takagi T, Ramirez CN, Radu C, Djaballah H: Live-cell imaging of caspase activation for high-content screening. J Biomol Screen (2009) 14(8):956-969.
52. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR: Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood (2005) 106(8):2841-2848.
53. Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, Ross L, Galinsky I, Davis TN, Silver SJ, Root DE et al: Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell (2009) 16(4):281-294.
54. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M et al: The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 313(5795):1929-1935.
55. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub TR et al: Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 10(4):331-342.
56. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Frohling S et al: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 462(7269):108-112.
57. Bush CR, Havens JM, Necela BM, Su W, Chen L, Yanagisawa M, Anastasiadis PZ, Guerra R, Luxon BA, Thompson EA: Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor and calcium signaling in human colorectal cancer cells. J Biol Chem (2007) 282(32): 23387-23401.
58. Kolfschoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM, Agami R: A genetic screen identifies PITX1 as a suppressor of Ras activity and tumorigenicity. Cell (2005) 121(6):849-858.
59. Aza-Blanc P, Cooper CL, Wagner K, Batalov S, Deveraux QL, Cooke MP: Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell (2003) 12(3):627-637.
60. Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ, Depinho RA et al: A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 121(6):837-848.
61. Hattori H, Zhang X, Jia Y, Subramanian KK, Jo H, Loison F, Newburger PE, Luo HR: RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells. Blood (2007) 110(2):640-650.
62. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, Takatsu Y et al: Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell (2008) 133(6):1006-1018.
63. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 12(4):395-402.
64. Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, Pomeroy SL et al: The kinesin KIF1B- acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 22(7):884-893.
65. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, Golub TR: Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 451(7176):335-339.
66. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R et al: Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 16(1):49-58.
67. Witt AE, Hines LM, Collins NL, Hu Y, Gunawardane RN, Moreira D, Raphael J, Jepson D, Koundinya M, Rolfs A, Taron B et al: Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J Proteome Res (2006) 5(3):599-610.
68. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448(7153):561-566.
69. Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M et al: Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA (2009): doi:10.1073/ pnas.0911726107.
70. Park J, Hu Y, Murthy TV, Vannberg F, Shen B, Rolfs A, Hutti JE, Cantley LC, Labaer J, Harlow E, Brizuela L: Building a human kinase gene repository: Bioinformatics, molecular cloning, and functional validation. Proc Natl Acad Sci USA (2005) 102(23):8114-8119.
71. Varjosalo M, Bjorklund M, Cheng F, Syvanen H, Kivioja T, Kilpinen S, Sun Z, Kallioniemi O, Stunnenberg HG, He WW, Ojala P et al: Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling. Cell (2008) 133(3):537-548.
72. Guarente L: Synthetic enhancement in gene interaction: A genetic tool come of age. Trends Genet (1993) 9(10):362-366.
73. Kroll ES, Hyland KM, Hieter P, Li JJ: Establishing genetic interactions by a synthetic dosage lethality phenotype. Genetics (1996) 143(1):95-102.
74. Tong AH, Evangelista M, Parsons AB, Xu H, Bader GD, Page N, Robinson M, Raghibizadeh S, Hogue CW, Bussey H, Andrews B et al: Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science (2001) 294(5550): 2364-2368.
75. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH: Integrating genetic approaches into the discovery of anticancer drugs. Science (1997) 278(5340):1064-1068.
76. Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell (2009) 136(5): 823-837.
77. Kaelin WG Jr: The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 5(9):689-698.
78. Kaelin WG Jr: Synthetic lethality: A framework for the development of wiser cancer therapeutics. Genome Med (2009) 1(10):99.
79. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434(7035):913-917.
80. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434(7035):917-921.
81. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 361(2):123-134.
82. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 4(10):814-819.
83. Bidere N, Ngo VN, Lee J, Collins C, Zheng L, Wan F, Davis RE, Lenz G, Anderson DE, Arnoult D, Vazquez A et al: Casein kinase 1- governs antigen-receptor-induced NF-B activation and human lymphoma cell survival. Nature (2009) 458(7234):92-96.
84. Kim SY, Dunn IF, Firestein R, Gupta P, Wardwell L, Repich K, Schinzel AC, Wittner B, Silver SJ, Root DE, Boehm JS et al: CK1- is required for breast cancers dependent on -catenin activity. PLoS One (2010) 5(2):e8979.
85. Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, Moreau LA, Shimamura A, D'Andrea AD: Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest (2007) 117(5): 1440-1449.
86. Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E, Kaelin WG Jr, Grueneberg DA: Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA (2008) 105(43):16484-16489.
87. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, Xie XJ et al: Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 446(7137): 815-819.
88. MacKeigan JP, Murphy LO, Blenis J: Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol (2005) 7(6): 591-600.
89. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, Elustondo F, Chang J, Temple J, Ahmed AA, Brenton JD et al: Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell (2007) 11(6):498-512.
90. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, Warrener P et al: Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol (2006) 26(24):9377-9386.
91. Rottmann S, Wang Y, Nasoff M, Deveraux QL, Quon KC: A TRAIL receptor-dependent synthetic lethal relationship between Myc activation and GSK3-/FBW7 loss of function. Proc Natl Acad Sci USA (2005) 102(42):15195-15200.
92. Lam LT, Davis RE, Ngo VN, Lenz G, Wright G, Xu W, Zhao H, Yu X, Dang L, Staudt LM: Compensatory IKK- activation of classical NF-B signaling during IKK- inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci USA (2008) 105(52):20798-20803.
93. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR et al: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14(12):1351-1356.
94. Sarthy AV, Morgan-Lappe SE, Zakula D, Vernetti L, Schurdak M, Packer JC, Anderson MG, Shirasawa S, Sasazuki T, Fesik SW: Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther (2007) 6(1):269-276.
95. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 137(5):835-848.
96. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Dohner K et al: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 137(5):821-834.
97. Chien Y, Kim S, Bumeister R, Loo YM, Kwon SW, Johnson CL, Balakireva MG, Romeo Y, Kopelovich L, Gale M Jr, Yeaman C et al: RalB GTPase-mediated activation of the I-B family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell (2006) 127(1):157-170.